ELCC 2023 | Managing low-grade immunotherapy-associated toxicity in lung cancer

Milica Kontic Jovanovic, MD, PhD, Clinical Center of Serbia, Belgrade, Serbia, discusses how certain relative contraindications have shifted to absolute contraindications for immunotherapy treatment as our knowledge of immunotherapy-associated toxicity has progressed. Dr Jovanovic also comments on the common line of practice following immunotherapy-associated toxicity, which is the discontinuation of immunotherapy or administration of glucocorticoids. This interview took place at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.